LIND RESEARCH
Research Note | Premium Equity Research
Lands Two Swiss Deals in 17 Days
Physitrack (PTRK) today announced its second institutional deal in Switzerland in less than three weeks. The latest agreement, a four-year contract with a leading Swiss hospital and rehabilitation group specializing in high-end surgery and research-driven prevention, is valued at CHF 150,000 with CHF 75,000 recognized in the first year. This follows a March 10 deal with a nationwide independent hospital group worth CHF 150,000 over four years (~EUR 39,000 ARR). Combined, the two deals contribute roughly EUR 117,000 in 2026 revenue, representing just over 1% of Lifecare's annual revenue base. The direct impact on our projections is minor, but obviously welcomed.
The Real Signal
The bigger signal is commercial traction. PTRK has historically grown through individual practitioner sign-ups; winning institutional hospital group contracts is a different sales motion entirely. Two in quick succession, in a premium market like Switzerland, suggest the enterprise go-to-market is maturing. The second deal is also structurally richer, including bespoke platform components and customized modules spanning the full care continuum from prevention through post-operative recovery. That kind of clinical workflow integration raises switching costs materially and supports the wide-moat thesis we have outlined for Lifecare. If this playbook is replicable across geographies, the growth profile improves.
PTRK trades at SEK 8.8, implying a significant margin against our SOTP valuation of SEK 22-25. Three forces keep the stock pinned at these levels.
First, Physitrack is mid-transition: the Wellness restructuring (Wellnow MBO, Fysiotest divestment, clinic closures) has depressed reported numbers with write-downs and EO items, masking underlying profitability that we estimate at 37% adjusted EBITDA margins on a pro forma basis. I also continue to weigh on investors' understanding of Lifecare's real quality.
Second, the broader AI-driven repricing of SaaS has weighed indiscriminately on the sector; we do not believe this applies to Physitrack, where the product is low-cost, deeply embedded in practitioners' workflows with a physical end user, and operates in a regulated environment that raises barriers for AI-native disruptors.
Third, persistent outflows from Nordic micro and small-cap funds continue to suppress sentiment across the segment, regardless of company-specific fundamentals.
Together, these create what we view as a textbook mispriced-and-misunderstood setup. The deals themselves will not close the valuation gap, but they add to a pattern of improving commercial traction that the market is not yet crediting. The bigger catalyst remains a US deal announcement. Hiring activity in the region and management commentary during the Q4 2025 earnings call imply meaningful traction building stateside, and a US institutional contract would carry a fundamentally different scale and signaling effect. How quickly the stock re-rates to our SEK 22-25 range depends on sentiment shifting, which we believe strong growth and a visible US win over the coming quarters can trigger.
We rate PTRK as Outperform with a target range of SEK 22-25 over 12-18 months. Read our latest deep-dive here.
Disclaimer
This analysis represents the independent views of Lind Research and is based on publicly available information believed to be reliable, but no warranty is given as to its accuracy or completeness. Nothing herein is investment advice or a recommendation. We publish openly, and companies do not influence our conclusions. Lind Research may hold positions in securities discussed.
Analyst owns shares? Yes
Lind Research